Inside USP: Modernizing the Compendia - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inside USP: Modernizing the Compendia
Industry participation is crucial as USP embarks on far-reaching monograph modernization initiative. This is an online-exclusive article.


Pharmaceutical Technology
Volume 34, Issue 9

Answering the calls of regulators and pharmaceutical manufacturers, the US Pharmacopeial Convention (USP) recently launched an initiative to identify standards in the USP-National Formulary (NF) compendia that maybe outdated, and to modernize them. USP will direct substantial energy and resources toward this effort during its 2010-2015 cycle, which commenced following the USP Convention meeting in April 2010. Key to the organization's success on this project—which will ultimately benefit patients, practitioners, manufacturers, and regulators—will be the participation of the pharmaceutical industry. USP hopes to collaborate closely with industry on this important activity.

The monograph modernization initiative is an outgrowth of feedback that USP has received during the past few years indicating that the organization should focus not only on developing new standards for medicines and their ingredients, but also on updating existing standards. This modernization effort will concentrate on small molecule and excipient monographs as well as certain biologics.

Updates to the monographs included in this effort are necessary for a variety of reasons—use of outdated technology (e.g, packed gas chromatography columns), existence of safety/environmental concerns (e.g, chlorinated solvents), or missing procedures for key aspects such as impurities, among others. Attention to monograph updating has been increasing, reflecting the reality that some of these monographs are roughly 40 to 50 years old. There are significant issues that need to be addressed within the monographs, and USP consequently views the project as a vital public health activity. This sentiment has been echoed by the US Food and Drug Administration. Commissioner Margaret Hamburg noted at the 2010 USP Convention in April 2010 that "one of the most pressing tasks before us [is] updating monographs... Now, we must jointly identify drug ingredients and products that would benefit from an up-to-date monograph... starting with those that have the greatest impact on public health."

Monograph prioritization

As a starting point on this stepped-up effort, USP prioritized a list of 200 small molecule and 96 excipient monographs from the more than 4000 standards included in the USP-NF and posted the list on its website (accessible at http://www.usp.org/USPNF/submitMonograph/improveMon.html). USP examined data on patient use of the medicines (indicating public health impact), as well as the level of use of the monographs by the pharmaceutical industry (indicating manufacturer reliance on these standards). Monographs identified for updates cut across all therapeutic categories. The list is presented on the USP website as a downloadable spreadsheet, which includes information on what procedure needs modernization and the current status of the modernization. Some monographs have more than one procedure in need of modernization. USP is updating the monograph status on this list on the last Friday of every month.

Although USP is using its own laboratories to support this activity, active participation by industry is encouraged, and considered absolutely essential to accomplish the goals set forward. USP hopes this participation will take several forms, including donation of procedures with supporting validation data and associated bulk reference standard material (for situations in which new reference standards are introduced), as well as involvement in the public review process.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here